Two Astellas execs earn $1 million-plus
This article was originally published in Scrip
Astellas's top two executives both earned well over $1 million in salary, bonus and stock options last fiscal year, triggering the disclosure of their remuneration packages under new Japanese accounting rules.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.